WINT · Windtree Therapeutics Inc /De/
$0.00
+0.00 (+0.00%)
At close · Jul 29
Going-concern doubt
— flagged Nov 19, 2025
Substantial doubt about the company's ability to continue as a going concern.
“We do *not* have sufficient cash and cash equivalents as of the date of this Quarterly Report on Form *10*-Q to support our operations for at least the *12* months following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern. To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans to secure additional capital, potentially through a combination of public or private securities offerings, convertible debt financings, and/or strategic transactions, including potential licensing arrangements, alliances, and drug product collaborations focused on specified geographic markets; however, *none* of these alternatives are committed at this time.”View the 10-Q filed Nov 19, 2025
Market Cap
$337,087
Shares
33.71M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Capacity | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2023-11-09 | — | — | 2024-03-31 | 2025-01-03 expired | 10-Q , filed 2025-11-19 |